Search results for "LUDI"

showing 10 items of 753 documents

Cytokeratin-18 fragments predict treatment response and overall survival in gastric cancer in a randomized controlled trial

2018

Background:Gastric cancer is common malignancy and exhibits a poor prognosis. At the time of diagnosis, the majority of patients present with metastatic disease which precludes curative treatment. Non-invasive biomarkers which discriminate early from advanced stages or predict the response to treatment are urgently required. This study explored the cytokeratin-18 fragment M30 and full-length cytokeratin-18 M65 in predicting treatment response and survival in a randomized, placebo-controlled trial of advanced gastric cancer.Methods:Patients enrolled in the SUN-CASE study received sunitinib or placebo as an adjunct to standard therapy with leucovorin (Ca-folinate), 5-fluorouracil, and irinote…

AdultMale0301 basic medicineOncologymedicine.medical_specialtyIndolesmedicine.medical_treatmentLeucovorinAntineoplastic AgentsPlaceboDisease-Free SurvivalMetastasislaw.inventionPlacebos03 medical and health sciences0302 clinical medicineRandomized controlled trialStomach NeoplasmslawInternal medicineAntineoplastic Combined Chemotherapy ProtocolsBiomarkers TumorSunitinibHumansMedicinePyrrolesProgression-free survivalRC254-282AgedAged 80 and overChemotherapyKeratin-18business.industrySunitinibCancerNeoplasms. Tumors. Oncology. Including cancer and carcinogensGeneral MedicineMiddle Agedmedicine.diseasePeptide FragmentsIrinotecan030104 developmental biology030220 oncology & carcinogenesisCamptothecinFemaleFluorouracilbusinessmedicine.drugTumor Biology
researchProduct

Hypoxia-Inducible Factor 2α Mutation-Related Paragangliomas Classify as Discrete Pseudohypoxic Subcluster

2016

Contains fulltext : 172720.pdf (Publisher’s version ) (Open Access) Recently, activating mutations of the hypoxia-inducible factor 2alpha gene (HIF2A/EPAS1) have been recognized to predispose to multiple paragangliomas (PGLs) and duodenal somatostatinomas associated with polycythemia, and ocular abnormalities. Previously, mutations in the SDHA/B/C/D, SDHAF2, VHL, FH, PHD1, and PHD2 genes have been associated with HIF activation and the development of pseudohypoxic (cluster-1) PGLs. These tumors overlap in terms of tumor location, syndromic presentation, and noradrenergic phenotype to a certain extent. However, they also differ especially by clinical outcome and by presence of other tumors o…

AdultMale0301 basic medicineOriginal articleCancer ResearchAdolescentMicroarraySDHBSDHABiologylcsh:RC254-282Oxidative PhosphorylationParagangliomaYoung Adult03 medical and health sciences0302 clinical medicineParagangliomaBasic Helix-Loop-Helix Transcription FactorsmedicineJournal ArticleCluster AnalysisHumansChildHypoxiaAgedGeneticsGene Expression ProfilingVascular damage Radboud Institute for Molecular Life Sciences [Radboudumc 16]Middle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasePhenotypeGene Expression Regulation NeoplasticGene expression profiling030104 developmental biologyHypoxia-inducible factors030220 oncology & carcinogenesisMutationFemaleSDHDTranscriptomeProtein BindingNeoplasia
researchProduct

Does access to care play a role in liver cancer survival? The ten-year (2006–2015) experience from a population-based cancer registry in Southern Ita…

2021

Abstract Background Hepatocellular carcinoma (HCC) is the most frequent primary invasive cancer of the liver. During the last decade, the epidemiology of HCC has been continuously changing in developed countries, due to more effective primary prevention and to successful treatment of virus-related liver diseases. The study aims to examine survival by level of access to care in patients with HCC, for all patients combined and by age. Methods We included 2018 adult patients (15–99 years) diagnosed with a primary liver tumour, registered in the Palermo Province Cancer Registry during 2006–2015, and followed-up to 30 October 2019. We obtained a proxy measure of access to care by linking each re…

AdultMaleCancer Researchmedicine.medical_specialtyCarcinoma HepatocellularAdolescentContext (language use)access to care cancer registries liver cancer public health survival Adolescent AdultAge Distribution Aged Aged 80 and over Carcinoma Hepatocellular Decision Making Organizational Decision Support Techniques Female Follow-Up Studies Health Services Accessibility Health Services Needs and Demand Humans Italy Liver Neoplasms Male Middle Aged Registries Survival Analysis Young AdultSettore MED/42 - Igiene Generale E Applicatalcsh:RC254-282survivalHealth Services AccessibilityDecision Support Techniquesliver cancerYoung AdultAge DistributionInternal medicineHealth careEpidemiologyGeneticsmedicineHumansRegistriesDecision Making OrganizationalAgedAged 80 and overaccess to careHealth Services Needs and Demandbusiness.industryPublic healthLiver Neoplasmspublic healthMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseSurvival AnalysisCancer registryItalyOncologycancer registriesHepatocellular carcinomaAmbulatoryFemaleLiver cancerbusinessFollow-Up StudiesResearch ArticleBMC Cancer
researchProduct

Downregulation of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) in human hepatocellular carcinoma and their prognostic significance

2012

Abstract Background Organic cation transporters (OCT) are responsible for the uptake and intracellular inactivation of a broad spectrum of endogenous substrates and detoxification of xenobiotics and chemotherapeutics. The transporters became pharmaceutically interesting, because OCTs are determinants of the cytotoxicity of platin derivates and the transport activity has been shown to correlate with the sensitivity of tumors towards tyrosine kinase inhibitors. No data exist about the relevance of OCTs in hepatocellular carcinoma (HCC). Methods OCT1 (SLC22A1) and OCT3 (SLC22A3) mRNA expression was measured in primary human HCC and corresponding non neoplastic tumor surrounding tissue (TST) by…

AdultMaleCancer Researchmedicine.medical_specialtyCarcinoma HepatocellularOrganic Cation Transport ProteinsHepatocellular carcinomaBlotting WesternDown-RegulationOCT3Real-Time Polymerase Chain ReactionOCT1lcsh:RC254-282SLC22A3Downregulation and upregulationInternal medicineGeneticsmedicineHumansRNA MessengerHCCTyrosineSLC22A3CytotoxicitySLC22A1AgedAged 80 and overOrganic cation transport proteinsbiologybusiness.industryLiver NeoplasmsOrganic Cation Transporter 1TransporterMiddle AgedPrognosislcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseSurvival AnalysisNeoplasm ProteinsEndocrinologyOncologyHepatocellular carcinomaCancer researchbiology.proteinFemalebusinessTyrosine kinaseResearch ArticleBMC Cancer
researchProduct

Impact of relative dose intensity of oxaliplatin in adjuvant therapy among stage III colon cancer patients on early recurrence: a retrospective cohor…

2020

Abstract Background Oxaliplatin-based therapy with FOLFOX-4 or CAPOX administered over 6 months remains the standard adjuvant treatment for stage III colon cancer (CC) patients. However, many patients experience dose reduction or early termination of chemotherapy due to oxaliplatin toxicity, which may increase the risk of early recurrence. The objective of this study was to analyze the relationship between the relative dose intensity of oxaliplatin (RDI-O) and early recurrence among stage III CC patients. Methods The study included 365 patients treated at five oncology centers in Poland between 2000 and 2014. Survival analysis was performed using the Kaplan-Meier method. Univariate analysis…

AdultMaleCancer Researchmedicine.medical_specialtyColorectal cancerGastroenterology03 medical and health sciences0302 clinical medicineInternal medicineGeneticsAdjuvant therapyMedicineHumans030212 general & internal medicineRelative dose intensityRC254-282Survival analysisAgedNeoplasm StagingRetrospective StudiesAged 80 and overUnivariate analysisbusiness.industryCumulative doseProportional hazards modelNeoplasms. Tumors. Oncology. Including cancer and carcinogensRetrospective cohort studyMiddle Agedmedicine.diseaseCumulative doseOxaliplatinColon cancerAdjuvant chemotherapyOxaliplatinOncologyChemotherapy Adjuvant030220 oncology & carcinogenesisColonic NeoplasmsFemaleNeoplasm Recurrence Localbusinessmedicine.drugResearch Article
researchProduct

Developments in esophageal surgery for adenocarcinoma: a comparison of two decades

2007

Abstract Background The objective of this study was to examine outcomes in patients undergoing esophageal resection for adenocarcinoma at our institution during a 20-year period and, in particular, to address temporal trends in long-term survival. Methods Out of 470 patients who underwent esophagectomy for malignancy between September 1985 and September 2005, a total number of 175 patients presented with esophageal adenocarcinoma. Patients enrolled in this study included AEG (adenocarcinoma of the esophagogastric junction) type I tumors only. Time trends were studied comparing two decades, 9/1985 to 9/1995 (DI) and 10/1995 to 9/2005 (DII). Results The overall survival was significantly more…

AdultMalemedicine.medical_specialtyCancer ResearchTime FactorsEsophageal Neoplasmsmedicine.medical_treatmentAdenocarcinomaMalignancylcsh:RC254-282Disease-Free SurvivalSurgical oncologymedicineGeneticsHumansSurvivorsEsophagusSurvival analysisAgedNeoplasm StagingRetrospective Studiesbusiness.industryRetrospective cohort studyMiddle AgedPrognosislcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseCombined Modality TherapySurvival AnalysisSurgeryEsophagectomyLog-rank testTreatment Outcomemedicine.anatomical_structureOncologyEsophagectomyLymph Node ExcisionAdenocarcinomaFemalebusinessResearch ArticleBMC Cancer
researchProduct

Population-based study of ovarian cancer in Côte d'Or: prognostic factors and trends in relative survival rates over the last 20 years

2010

Abstract Background The aim of this population-based study was to assess independent prognostic factors in ovarian cancer using relative survival (RS) and to investigate changes in RS rates from 1982 to 2005. Methods Data on 748 patients with ovarian cancer were provided by the Côte d'Or gynaecologic cancer registry. The RS was estimated using a generalized linear model with a Poisson error structure. Relative survival and its 95% confidence interval (CI) were described at the following specific time points 1, 3 and 5 years. The effect of prognostic factors on survival was assessed with multivariate analyses of RS. Results The median follow-up was 12 years. The RS rates at 1, 3 and 5 years …

AdultOncologymedicine.medical_specialtyCancer ResearchMultivariate analysisAdolescentPopulationMedical Oncologylcsh:RC254-282Internal medicinemedicineGeneticsHumansRegistriesChildeducationSurvival rateAgedAged 80 and overOvarian NeoplasmsGynecologyeducation.field_of_studyRelative survivalbusiness.industryCancerMiddle AgedPrognosislcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseConfidence intervalSurvival RateSerous fluidTreatment OutcomeOncologyFemaleFranceOvarian cancerbusinessResearch ArticleBMC Cancer
researchProduct

For patients with breast cancer, geographic and social disparities are independent determinants of access to specialized surgeons. A eleven-year popu…

2012

Abstract Background It has been shown in several studies that survival in cancer patients who were operated on by a high-volume surgeon was better. Why then do all patients not benefit from treatment by these experienced surgeons? The aim of our work was to study the hypothesis that in breast cancer, geographical isolation and the socio-economic level have an impact on the likelihood of being treated by a specialized breast-cancer surgeon. Methods All cases of primary invasive breast cancer diagnosed in the Côte d’Or from 1998 to 2008 were included. Individual clinical data and distance to the nearest reference care centre were collected. The Townsend Index of each residence area was calcul…

AdultRural PopulationCancer Researchmedicine.medical_specialtyGeographical isolationBreast Neoplasms[SDV.CAN]Life Sciences [q-bio]/CancerPopulation basedlcsh:RC254-282Health Services Accessibility[ SDV.CAN ] Life Sciences [q-bio]/Cancer03 medical and health sciences0302 clinical medicineBreast cancer[SDV.CAN] Life Sciences [q-bio]/CancerSurgical oncologyGeneticsmedicineHumans030212 general & internal medicineRegistriesHealthcare DisparitiesAgedNeoplasm StagingGynecologybusiness.industryMultilevel modelCancerMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasePrognosis3. Good healthsurgical procedures operativeOncologySocioeconomic Factors030220 oncology & carcinogenesisFamily medicineMultilevel AnalysisNeoplasm stagingFemalebusinessRural populationResearch Article
researchProduct

Bidirectional within- and between-person relations between physical activity and cognitive function

2022

Abstract Objectives To examine bidirectional within- and between-person relations between physical activity and cognitive function across 15 years. Methods Participants (N = 1,722, age range 40–85 years, 55% women) were drawn from the Betula prospective cohort study. We included 4 waves of data. Bivariate latent curve models with structured residuals were estimated to examine bidirectional within- and between-person relations between physical activity and cognitive function (episodic memory recall, verbal fluency, visuospatial ability). Results We observed no statistically significant bidirectional within-person relations over time. Higher levels of physical activity at baseline were relate…

Aged 80 and overMalePsykologiSocial PsychologyPsykologi (exklusive tillämpad psykologi)Memory EpisodicVDP::Medisinske Fag: 700::Idrettsmedisinske fag: 850Psychology (excluding Applied Psychology)Clinical PsychologyCognitionMental RecallHumansPsychologyAdultsReciprocal relationsFemaleProspective StudiesGeriatrics and GerontologyGerontologyExerciseAged
researchProduct

Semi-Mechanistic Model for the Antitumor Response of a Combination Cocktail of Immuno-Modulators in Non-Inflamed (Cold) Tumors.

2021

Simple Summary The clinical efficacy of immunotherapies when treating cold tumors is still low, and different treatment combinations are needed when dealing with this challenging scenario. In this work, a middle-out strategy was followed to develop a model describing the antitumor efficacy of different immune-modulator combinations, including an antigen, a toll-like receptor-3 agonist, and an immune checkpoint inhibitor in mice treated with non-inflamed tumor cells. Our results support that clinical response requires antigen-presenting cell activation and also relies on the amount of CD8 T cells and tumor resistance mechanisms present. This mathematical model is a very useful platform to ev…

AgonistCancer ResearchProgrammed cell deathmedicine.drug_classmedicine.medical_treatmentcold tumorscombination of therapeuticsArticleAntigenmedicinepreclinicalDoubling timeimmuno-oncologyRC254-282biologybusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensImmunotherapydrug developmentmechanistic modelingOncologyDrug developmentCancer researchbiology.proteinAntibodybusinessCD8Cancers
researchProduct